Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents

Antimicrobial Agents and Chemotherapy
Kim CreditoPeter C Appelbaum

Abstract

The MICs of LBM415, a new peptide diformylase inhibitor, were </=0.06 to 4.0 microg/ml for 258 isolates of Staphylococcus aureus and coagulase-negative staphylococci. LBM415 MICs were similar irrespective of whether the strains were methicillin susceptible or resistant. All strains were also susceptible to vancomycin, linezolid, ranbezolid, daptomycin, oritavancin, and quinupristin-dalfopristin. LBM415 at the MIC was bacteriostatic after 24 h.

References

Jan 1, 1994·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A VossI Braveny
Oct 23, 1997·Antimicrobial Agents and Chemotherapy·F BiavascoP E Varaldo
Oct 8, 1999·The Journal of Antimicrobial Chemotherapy·R L Nichols
Mar 16, 2000·Drugs·D I Diekema, R N Jones
Jul 18, 2000·Antimicrobial Agents and Chemotherapy·H W BoucherG M Eliopoulos
Sep 12, 2000·The Journal of Antimicrobial Chemotherapy·D M Livermore
Nov 18, 2000·Antimicrobial Agents and Chemotherapy·D R SnydmanJ M Boyce
Jan 11, 2001·The Journal of Antimicrobial Chemotherapy·E CercenadoE Bouza
Feb 13, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E Draghijeva
Feb 13, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C Cuny, W Witte
Dec 21, 2002·The Journal of Antimicrobial Chemotherapy·Ronald N Jones, Paul R Rhomberg
Jul 5, 2003·International Journal of Antimicrobial Agents·Tamara R AndereggUNKNOWN Quality Control Working Group
Oct 18, 2003·The Journal of Antimicrobial Chemotherapy·Bulent BozdoganPeter C Appelbaum
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Fred C TenoverBülent Bozdogan
Feb 6, 2004·Diagnostic Microbiology and Infectious Disease·Tamara R AndereggUNKNOWN Quality Control Working Group
Sep 10, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·T R FritscheR N Jones

❮ Previous
Next ❯

Citations

Jul 4, 2012·Acta Crystallographica. Section D, Biological Crystallography·Sang Jae LeeSe Won Suh
Jul 15, 2009·Antimicrobial Agents and Chemotherapy·Colin S OsborneNeil S Ryder
Jun 28, 2006·Antimicrobial Agents and Chemotherapy·Tatiana BogdanovichPeter C Appelbaum
Sep 30, 2009·Antimicrobial Agents and Chemotherapy·Ruth E CaughlanCharles R Dean
Mar 13, 2013·Antimicrobial Agents and Chemotherapy·Karen O'DwyerDeborah Butler
Mar 29, 2005·Antimicrobial Agents and Chemotherapy·Thomas R FritscheRonald N Jones
Mar 11, 2005·Expert Opinion on Investigational Drugs·Michael N Alekshun
Jan 25, 2007·Expert Opinion on Investigational Drugs·Garyphallia Poulakou, Helen Giamarellou
Sep 8, 2005·Expert Opinion on Investigational Drugs·D Chen, Z Yuan
Dec 25, 2009·Pharmacotherapy·Michael T Guskey, Brian T Tsuji
Aug 16, 2005·Current Opinion in Microbiology·Peter C Appelbaum, Michael R Jacobs
Nov 18, 2005·Biochemical Pharmacology·Zhengyu Yuan, Richard J White
Oct 30, 2013·Antimicrobial Agents and Chemotherapy·Deborah ButlerMagdalena Zalacain
Jan 15, 2005·The Journal of Antimicrobial Chemotherapy·Jan M BellRonald N Jones

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.